CPT code 86413 represents a quantitative immunoassay to measure antibodies to the SARS–CoV–2 virus in a patient specimen, typically blood. As a clinically focused laboratory code, it captures services that quantify immune response and is relevant for post-infection or post-vaccination assessment. Nationally, demand for SARS–CoV–2 antibody testing has implications for laboratory capacity, payer coverage policies, and clinical interpretation of serology results.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for antibody quantification, typical sites where the service is performed, and the national policy considerations that affect coverage and billing. The publication also reviews common modifiers and reporting practices, reimbursement benchmarks where available, and how this service fits into broader laboratory and infectious disease care pathways.

This summary delivers practical, policy-focused information for laboratory administrators, billing professionals, and payers seeking clarity on CPT code 86413 and its role in SARS–CoV–2 serologic testing.